Skip to search formSkip to main contentSkip to account menu

celecoxib

Known as: 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, Celecoxib [Chemical/Ingredient], Célécoxib 
A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity… 
National Institutes of Health

Related topics

Related topics

35 relations
Adenomatous Polyposis ColiAngiogenesis InhibitionCYP2C9 protein, humanCelecoxib:MCnc:Pt:Ser/Plas:Qn

Broader (2)

Anti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2 Inhibitors

Narrower (3)

CelebrexSC 58635celecoxib-NBD

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Sulfonamide inhibition studies of the γ-carbonic anhydrase from the oral pathogen Porphyromonas gingivalis.
Highly Cited
2014
Highly Cited
2014
Synthesis, docking simulation, biological evaluations and 3D-QSAR study of 5-Aryl-6-(4-methylsulfonyl)-3-(metylthio)-1,2,4-triazine as selective cyclooxygenase-2 inhibitors.
Highly Cited
2010
Highly Cited
2010
The analgesic and anti-inflammatory effect of WIN-34B, a new herbal formula for osteoarthritis composed of Lonicera japonica Thunb and Anemarrhena asphodeloides BUNGE in vivo.
Highly Cited
2009
Highly Cited
2009
Mechanisms operated by endothelin ETA and ETB receptors in the trigeminal ganglion contribute to orofacial thermal hyperalgesia induced by infraorbital nerve constriction in rats
Highly Cited
2006
Highly Cited
2006
Risks and benefits of celecoxib to prevent recurrent adenomas.
In late September 2004, the cardiovascular risks identified in a placebo-controlled adenoma-prevention trial that was terminated… 
Highly Cited
2006
Highly Cited
2006
High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma
Purpose: Angiogenesis is increased in aggressive histology non–Hodgkin's lymphoma and may be a target with selective… 
Highly Cited
2005
Highly Cited
2005
Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Review
2002
Review
2002
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease.
Review
2001
Review
2001
Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors.
Review
2001
Review
2001
The ever-emerging anti-inflammatories. Have there been any real advances?
  • K. Rainsford
  • Journal of Physiology - Paris
  • 2001
  • Corpus ID: 21440382
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)